Helix BioPharma Corp. Closes Private Placement, Extends Period to Exercise Warrants and Provides Corporate Update

World News: . []

RICHMOND HILL, Ontario, March 15, 2019 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX, FSE: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has closed a private placement financing for gross proceeds of CAD609,450.

The terms of the placement are for the purchase of units at $0.51 per unit. Each unit is comprised of one common share and one common share purchase warrant. Each common share purchase warrant will entitle the holder to purchase one common share at an exercise price of $0.72 and have an expiry of five years from the date of issuance. Helix intends to use the net proceeds of the private placement for working capital and research and development activities.

ACM Alpha Consulting Management AG provided financial advisory services to Helix in connection with the private placement.

The Company also announced that it has received conditional approval from the Toronto Stock Exchange (the “TSX”) to extend the exercise period of a total of 12,661,000 outstanding common share purchase warrants (the “Warrants”) issued pursuant to private placement financings of the Company between July 2014 and April 2015, representing approximately 11.8% of the Company’s issued and outstanding common shares. Of the 12,661,000 outstanding Warrants, to the knowledge of the Company, an aggregate of 3,862,000 Warrants are beneficially owned, directly or indirectly, or under the control or direction of, insiders of the Company (the “Insider Warrants”) and the remaining 8,799,000 Warrants are beneficially owned, directly or indirectly, or under the control or direction of, non-insiders (the “Non-Insider Warrants”).

The dates of each private placement financing, the original issue price of the units (with each unit comprised of one common share and one common share purchase warrant), the total number of Warrants, a breakdown of Insider Warrants and Non-Insider Warrants, the exercise price of the Warrants, the original expiry date and the proposed extended expiry date of the Warrants are as follows:

The Company intends to seek the approval of disinterested shareholders of the Company (“Shareholders”) to amend the Insider Warrants at the annual and special meeting of Shareholders to be held on April 15, 2019 (the “Meeting”). Subject to TSX approval, the expiry dates of the Warrants will be extended for a period of two years (i) effective March 29, 2019, in the case of the Non-Insider Warrants and (ii) effective on the date that disinterested Shareholder approval has been obtained, in the case of the Insider Warrants. The exercise price of the Warrants will remain unchanged.

As previously disclosed in a press release on February 11, 2019, the Company has been in discussions with a group which includes ACM Alpha Consulting Management AG to divest a majority stake in its wholly owned subsidiary, Helix Immuno-Oncology S.A. Negotiations regarding the proposed transaction are ongoing, however, they have not progressed to a stage where the proposed transaction can be included in the management information circular for approval by Shareholders at the Meeting.

Helix BioPharma Corp. is an immuno-oncology company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix’s product development initiatives include its novel L-DOS47 new drug candidate and Chimeric Antigen Receptor (“CAR”) based cell therapies. Helix is currently listed on the TSX and FSE under the symbol “HBP”.

Helix BioPharma Corp.9120 Leslie Street, Suite 205Richmond Hill, Ontario, L4B 3J9Tel: 905-841-2300Email:

More news and information about Helix BioPharma Corp.

Published By:

Globe Newswire: 21:30 GMT Friday 15th March 2019

Published: .

Search for other references to "helix" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.
Privacy Policy | Terms and Conditions | Contact Us